Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326699 | 0.86 | MEN1 (0.66) | KMT2AMEN1GFERHSP90AA1NPC1 | |
| SCHEMBL24430009 | 0.85 | MEN1 (0.61) | KMT2AMEN1GFERCA12CA9 | |
| SCHEMBL12671929 | 0.83 | CFTR (0.52) | KMT2AMEN1NPC1HTTRAB9A | |
| SCHEMBL24437325 | 0.82 | KMT2A (0.61) | KMT2AMEN1GFERCA12CA9 | |
| SCHEMBL26205808 | 0.82 | MEN1 (0.61) | KMT2AMEN1HSP90AA1NPC1MAPT | |
| SCHEMBL11036224 | 0.77 | KMT2A (0.71) | KMT2AMEN1HSP90AA1NPC1MAPT | |
| SCHEMBL24437317 | 0.76 | MEN1 (0.57) | KMT2AMEN1HSP90AA1MAPTMAPK1 | |
| SCHEMBL24430007 | 0.76 | MEN1 (0.50) | KMT2AMEN1GFERHSP90AA1MAPT | |
| SCHEMBL26205826 | 0.75 | MEN1 (0.52) | KMT2AMEN1HSP90AA1NPC1MAPT | |
| SCHEMBL24430013 | 0.75 | MEN1 (0.49) | KMT2AMEN1HSP90AA1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022109066-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE | SOUTHERN RESEARCH INSTITUTE (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, GLS, HMOX2 | KMT2A 2088/4885MEN1 4171/4885GFER 678/4885 |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | HMOX1, GLS, HMOX2 | KMT2A 2088/4885MEN1 4171/4885GFER 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.